Be my Valentine: Attractive gut assets win Elcelyx loving $20m
This article was originally published in Scrip
Executive Summary
Venture capital investors expressed their love for San Diego-based Elcelyx Therapeutics' type 2 diabetes drug candidate NewMet and over-the-counter weight loss supplement Lovidia on Valentine's Day by closing a $20 million Series C venture funding round to prepare the assets for partnerships and commercialization.